Gold bars to be exempt from tariffs, White House clarifies
COPENHAGEN - Ascendis Pharma A/S (NASDAQ:ASND) shares gained 2.9% after the biopharmaceutical company reported a narrower-than-expected second-quarter loss and revenue that exceeded analyst estimates, driven by strong sales of its YORVIPATH and SKYTROFA products.
The Denmark-based company posted a second-quarter loss of EUR0.82 per share, significantly better than analysts’ expectations of a EUR1.27 loss. Revenue surged to EUR158.05 million, beating the consensus estimate of EUR142.38 million and representing a 339% increase from EUR36.0 million in the same period last year.
The revenue growth was primarily fueled by YORVIPATH (palopegteriparatide), which generated EUR103.0 million, and SKYTROFA (lonapegsomatropin-tcgd), which contributed EUR50.7 million. The company reported continued uptake of YORVIPATH in the U.S., with approximately 3,100 unique patient enrollments and more than 1,500 prescribing healthcare providers as of June 30.
"With the robust global uptake of YORVIPATH and with TransCon CNP under U.S. FDA priority review, Ascendis is on the verge of bringing our third high-value medicine to patients and substantially transforming our financial profile," said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer.
The company’s TransCon CNP (navepegritide) is currently under FDA priority review for the treatment of children with achondroplasia, with a PDUFA date of November 30, 2025. Ascendis also received FDA approval for SKYTROFA for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
Research and development costs decreased to EUR72.0 million from EUR83.5 million a year earlier, while selling, general, and administrative expenses rose to EUR107.6 million from EUR74.3 million, reflecting continued commercial expansion.
As of June 30, 2025, Ascendis had cash and cash equivalents of EUR494 million, compared to EUR560 million at the end of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.